humans, this is an idea difficult to be tested. Thus, only an
extensive investigation of intracellular integrators and
modulators will shed more light on the signaling mecha-
nisms involved in this serious psychiatric disorder and its
treatment.
Acknowledgements This research was supported by grants from Eli
Lilly do Brazil, UNESC and CNPq.
References
1. Giros B, Jaber M, Jones SR et al (1996) Hyperlocomotion and
indifference to cocaine and amphetamine in mice lacking the
dopamine transporter. Nature 379:606–612
2. Packard MG, Knowlton BJ (2002) Learning and memory func-
tions of the Basal Ganglia. Annu Rev Neurosci 25:563–593
3. Lourenco GA, Dorce VA, Palermo-Neto J (2005) Haloperidol
treatments increased macrophage activity in male and female
rats: influence of corticosterone and prolactin serum levels. Eur
Neuropsychopharmacol 15:271–277
4. Kavelaars A, Cobelens PM, Teunis MA et al (2005) Changes in
innate and acquired immune responses in mice with targeted
deletion of the dopamine transporter gene. J Neuroimmunol
161:162–168
5. Seeman P (1992) Dopamine receptor sequences. Therapeutic
levels of neuroleptics occupy D2 receptors, clozapine occupies
D4. Neuropsychopharmacology 7:261–284
6. Bergson C, Levenson R, Goldman-Rakic PS et al (2003) Dopa-
mine receptor-interacting proteins: the Ca(2+) connection in
dopamine signaling. Trends Pharmacol Sci 24:486–492
7. Foubister V (2002) Do all paths lead to DARPP-32? Drug Discov
Today 7:1068–1070
8. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet
363:2063–2072
9. Souza BR, Souza RP, Rosa DV et al (2006) Dopaminergic
intracellular signal integrating proteins: relevance to schizo-
phrenia. Dialogues Clin Neurosci 8:95–100
10. Albert KA, Hemmings HC Jr, Adamo AI et al (2002) Evidence
for decreased DARPP-32 in the prefrontal cortex of patients with
schizophrenia. Arch Gen Psychiatry 59:705–712
11. Ishikawa M, Mizukami K, Iwakiri M, Asada T (2007) Immuno-
histochemical and immunoblot analysis of Dopamine and cyclic
AMP-regulated phosphoprotein, relative molecular mass 32,000
(DARPP-32) in the prefrontal cortex of subjects with schizo-
phrenia and bipolar disorder. Prog Neuropsychopharmacol Biol
Psychiatry [Epub ahead of print]
12. Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2
dopamine receptors in efflux of cyclic AMP from rat neostriatum.
Nature 294:366–368
13. Nishi A, Snyder GL, Greengard P (1997) Bidirectional regulation
of DARPP-32 phosphorylation by dopamine. J Neurosci
17:8147–8155
14. Svenningsson P, Lindskog M, Ledent C et al (2000) Regulation
of the phosphorylation of the dopamine- and cAMP-regulated
phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine
D2, and adenosine A2A receptors. Proc Natl Acad Sci USA
97:1856–1860
15. Lindskog M, Svenningsson P, Fredholm BB et al (1999)
Activation of dopamine D2 receptors decreases DARPP-
32 phosphorylation in striatonigral and striatopallidal projec-
tion neurons via different mechanisms. Neuroscience 88:
1005–1008
16. Svenningsson P, Nishi A, Fisone G et al (2004) DARPP-32: an
integrator of neurotransmission. Annu Rev Pharmacol Toxicol
44:269–296
17. Koh PO, Undie AS, Kabbani N et al (2003) Up-regulation of
neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of
schizophrenic and bipolar patients. Proc Natl Acad Sci USA
100:313–317
18. Bai J, He F, Novikova SI et al (2004) Abnormalities in the
dopamine system in schizophrenia may lie in altered levels of
dopamine receptor-interacting proteins. Biol Psychiatry 56:427–
440
19. Nakayama S, Moncrief ND, Kretsinger RH (1992) Evolution of
EF-hand calcium-modulated proteins. II. Domains of several
subfamilies have diverse evolutionary histories. J Mol Evol
34:416–448
20. Nef S, Fiumelli H, de Castro E et al (1995) Identification of
neuronal calcium sensor (NCS-1) possibly involved in the regu-
lation of receptor phosphorylation. J Recept Signal Transduct Res
15:365–378
21. Ames JB, Ishima R, Tanaka T et al (1997) Molecular mechanics
of calcium-myristoyl switches. Nature 389:198–202
22. O’Callaghan DW, Ivings L, Weiss JL et al (2002) Differential
use of myristoyl groups on neuronal calcium sensor proteins as a
determinant of spatio-temporal aspects of Ca
2+
signal transduc-
tion. J Biol Chem 277:14227–14237
23. O’Callaghan DW, Burgoyne RD (2003) Role of myristoylation in
the intracellular targeting of neuronal calcium sensor (NCS)
proteins. Biochem Soc Trans 31:963–965
24. Martone ME, Edelmann VM, Ellisman MH et al (1999) Cellular
and subcellular distribution of the calcium-binding protein NCS-1
in the central nervous system of the rat. Cell Tissue Res 295:395–
407
25. Kabbani N, Negyessy L, Lin R et al (2002) Interaction with
neuronal calcium sensor NCS-1 mediates desensitization of the
D2 dopamine receptor. J Neurosci 22:8476–8486
26. Callier S, Snapyan M, Le Crom S et al (2003) Evolution and cell
biology of dopamine receptors in vertebrates. Biol Cell 95:489–
502
27. Iwata K, Ito K, Fukuzaki A et al (1999) Dynamin and rab5
regulate GRK2-dependent internalization of dopamine D2
receptors. Eur J Biochem 263:596–602
28. Negyessy L, Goldman-Rakic PS (2005) Subcellular localization
of the dopamine D2 receptor and coexistence with the calcium-
binding protein neuronal calcium sensor-1 in the primate pre-
frontal cortex. J Comp Neurol 488:464–475
29. Seeman P (2006) Targeting the dopamine D2 receptor in
schizophrenia. Expert Opin Ther Targets 10:515–531
30. Reinke A, Martins MR, Lima MS et al (2004) Haloperidol and
clozapine, but not olanzapine, induces oxidative stress in rat
brain. Neurosci Lett 372:157–160
31. Polydoro M, Schro
¨
der N, Lima MNM et al (2004) Haloperidol-
and clozapine-induced oxidative stress in the rat brain. Pharmacol
Biochem Behav 78:751–756
32. Bradford MM (1976) A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem 72:248–254
33. Bonci A, Hopf FW (2005) The dopamine D2 receptor: new
surprises from an old friend. Neuron 47:335–338
34. Meyer-Lindenberg A, Straub RE, Lipska BK et al (2007) Genetic
evidence implicating DARPP-32 in human frontostriatal struc-
ture, function, and cognition. J Clin Invest 117:672–682
35. Grebb JA, Girault JA, Ehrlich M et al (1990) Chronic treatment
of rats with SCH-23390 or raclopride does not affect the con-
centrations of DARPP-32 or its mRNA in dopamine-innervated
brain regions. J Neurochem 55:204–207
Neurochem Res (2008) 33:533–538 537
123